Expression of COX-2 and steroid converting enzymes in breast cancer

Oncology Reports

Volumn 16, Issue 2, 2006, Pages 219-224

  Gunnarsson, Cecilia ^a   Jansson, Agneta ^a   Holmlund, Birgitta ^a   Ferraud, Lilianne ^a   Nordenskjold B O ^a   Rutqvist, Lars Erik ^b   Skoog, Lambert ^b   Stål, Olle ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

17 hydroxysteroid dehydrogenase; Aromatase; Breast cancer; COX 2

Indexed keywords

17 HYDROXYSTEROID DEHYDROGENASE II, HUMAN; 17-HYDROXYSTEROID DEHYDROGENASE II, HUMAN; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; AROMATASE; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; HYDROXYSTEROID DEHYDROGENASE;

ARTICLE; BREAST TUMOR; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS;

17-HYDROXYSTEROID DEHYDROGENASES; AROMATASE; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 33748578972     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.2.219     Document Type: Article

References (31)

1. Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
2. Wolff H, Saukkonen K, Anttilla S, et al: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998. (Pubitemid 28521147)
3. Yoshimura R, Sano H, Masuda C, et al: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589-596, 2000. (Pubitemid 30640105)
4. Tucker O, Dannenberg A, Yang E, et al: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999. (Pubitemid 29135954)
5. Hwang D, Scollard D, Byrne J, et al: Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998. (Pubitemid 28160637)
6. Soslow RA, Dannenberg AJ, Rush D, et al: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 15: 2637-2645, 2000. (Pubitemid 32011609)
7. Kirkpatrick K, Ogunkolade W, Elkak A, et al: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 18: 237-241, 2002.
8. Ristimäki A, Sivula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002. (Pubitemid 34126931)
9. Wülfing P, Diallo R, Müller C, et al: Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382, 2003. (Pubitemid 36995136)
10. Half E, Ming Tang X, Gwyn K, et al: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002. (Pubitemid 34408488)
11. Brodie AMH, Lu Q, Fulton A, et al: Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79: 41-47, 2001. (Pubitemid 34158777)
12. Brueggemeier RW, Richards JA and Petrel TA: Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 86: 501-507, 2003. (Pubitemid 37412590)
13. Yue W, Wang J, Hamilton C, et al: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58: 927-932, 1998. (Pubitemid 28182460)
14. Vihko P, Isomaa V, Ghosh D, et al: Structure and function of 17β-hydroxysteroid dehydrogenase type 1 and 2. Mol Cell Endocrinol 171: 71-76, 2001. (Pubitemid 32098199)
15. Peltoketo H, Luu-The V, Simard J, et al: 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 23: 1-11, 1999. (Pubitemid 29369554)
16. Miettinen M, Mustonen M, Poutanen M, et al: 17β-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res Treat 57: 175-182, 1999. (Pubitemid 29531462)
17. Gunnarsson C, Olsson B and Stål O: Abnormal expression of 17β-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res 61: 8448-8451, 2001. (Pubitemid 33131123)
18. Gunnarsson C, Hellqvist E and Stål O: 17β-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer 92: 547-552, 2005. (Pubitemid 40395536)
19. Zhao Y, Agarwal VR, Mendelson CR, et al: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137: 5739-5742, 1996. (Pubitemid 26423150)
20. Purohit A, Newman S and Reed M: The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 4: 65-69, 2002. (Pubitemid 34248122)
21. Miyoshi Y, Kim-Jin S, Akazawa K, et al: Down-regulation of intratumoral Aromatase messsenger RNA levels by Docetaxel in human breast cancers. Clin Cancer Res 10: 8163-8169, 2004. (Pubitemid 40053374)
22. Speirs V, Walton DS, Hall M-C, et al: In vivo and in vitro expression of steroiod-converting enzymes in human breast tumours: associations with interleukin-6. Br J Cancer 81: 690-695, 1999. (Pubitemid 29458867)
23. Sasano H, Frost A, Saitoh R, et al: Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 81: 4042-4046, 1996. (Pubitemid 26380415)
24. Oduwole O, Li Y, Isomaa V, et al: 17β-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 64: 7604-7609, 2004. (Pubitemid 39372106)
25. Gunnarsson C, Ahnström M, Kirschner K, et al: Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22: 34-40, 2003. (Pubitemid 36152881)
26. O'Connor J, Avent J, Lee J, et al: Cyclooxygenase -2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 58: 1034-1040, 2004. (Pubitemid 38314783)
27. Kelly LM, Hill ADK, Kennedy S, et al: Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29: 707-710, 2003. (Pubitemid 37483941)
28. Cleton-Jansen AM, Callen DF, Seshadri R, et al: Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumours reveals factors that influence delineation of candidate regions. Cancer Res 61: 1171-1177, 2001. (Pubitemid 32174440)
29. Elo JP, Harkonen P, Kyllonen AP, et al: Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 57: 3356-3359, 1997. (Pubitemid 27355474)
30. Koh E, Noda T, Kanaya J, et al: Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissue. Prostate 53: 154-159, 2002.
31. Kaminski T, Akinola L, Poutanen M, et al: Growth factors and phorbol-12-myristate-13-acetate modulate the follicle-stimulating hormone- and cyclic adenosine-3′,5′-monophosphate dependent regulation of 17β-hydroxysteroid dehydrogenase 1 expression in rat granulosa cells. Mol Cell Endocrinol 136: 47-56, 1997. (Pubitemid 28073659)